First Comparison of Amulet and Watchman FLX LAA Closure Devices Found Similar Outcomes

$ 14.50 · 4.9 (419) · In stock

Results from the SWISS-APERO Trial reported at TCT 2021 and published simultaneously in Circulation

Discoveries in Medicine -Squaring Off: Amplatzer Amulet and Watchman 2.5 Both Emerge Winners

Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device

TCT 2021: SWISS-APERO trial finds lower rate of peri-device leak in Amulet compared to Watchman FLX LAAC device - Cardiovascular News

Antithrombotic Therapy after Percutaneous Left Atrial Appendage Closure: Evidence, Challenges and Future Directions

Clinical Evidence - Boston Scientific

Preclinical assessment of a modified Occlutech left atrial appendage closure device in a porcine model

Structural Heart Occluders

Abbott Vascular

Abbott says study backs Amplatzer Amulet against Watchman FLX

Left Atrial Appendage Closure for Stroke Prevention

Real-world outcomes from the EU-PORIA registry of the FARAPULSE Pulsed Field Ablation (PFA) System

Left Atrial Appendage (LAA) Occluders

Cleveland Clinic-Led Trial Finds that Atrial Fibrillation Patients Undergoing TAVR and Watchman Procedures Together Have Similar Outcomes to Using Blood Thinners after TAVR